Together with evidence demonstrating the benefits of iron administration in heart failure, these effects of SGLT2 inhibitors on markers of iron metabolism suggest that improvements in iron utilization may contribute to their clinical benefits on heart failure–related outcomes [14]. The gene discussed is SLC5A2; the disease is heart failure.